Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX – Get Free Report) CEO Christopher Gibson sold 20,000 shares of the business’s stock in a transaction that occurred on Wednesday, September 4th. The shares were sold at an average price of $6.04, for a total transaction of $120,800.00. Following the completion of the transaction, the chief executive officer now directly owns 762,656 shares of the company’s stock, valued at approximately $4,606,442.24. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink.
Christopher Gibson also recently made the following trade(s):
- On Wednesday, August 7th, Christopher Gibson sold 30,000 shares of Recursion Pharmaceuticals stock. The shares were sold at an average price of $7.10, for a total transaction of $213,000.00.
- On Wednesday, July 10th, Christopher Gibson sold 50,000 shares of Recursion Pharmaceuticals stock. The shares were sold at an average price of $7.48, for a total transaction of $374,000.00.
Recursion Pharmaceuticals Price Performance
RXRX opened at $5.92 on Friday. The company has a quick ratio of 6.07, a current ratio of 6.07 and a debt-to-equity ratio of 0.04. Recursion Pharmaceuticals, Inc. has a 52-week low of $4.97 and a 52-week high of $15.74. The company has a 50 day moving average of $7.33 and a two-hundred day moving average of $8.85. The company has a market cap of $1.41 billion, a P/E ratio of -3.70 and a beta of 0.82.
Wall Street Analyst Weigh In
RXRX has been the subject of a number of recent analyst reports. Jefferies Financial Group lowered their target price on shares of Recursion Pharmaceuticals from $8.00 to $6.00 and set a “hold” rating for the company in a report on Tuesday. Leerink Partners lowered their target price on shares of Recursion Pharmaceuticals from $9.00 to $8.00 and set a “market perform” rating for the company in a report on Tuesday. KeyCorp lowered their target price on shares of Recursion Pharmaceuticals from $16.00 to $12.00 and set an “overweight” rating for the company in a report on Thursday, July 11th. Finally, Needham & Company LLC lowered their target price on shares of Recursion Pharmaceuticals from $16.00 to $11.00 and set a “buy” rating for the company in a report on Wednesday. Four investment analysts have rated the stock with a hold rating and two have issued a buy rating to the stock. Based on data from MarketBeat, Recursion Pharmaceuticals has an average rating of “Hold” and an average price target of $9.40.
View Our Latest Stock Report on Recursion Pharmaceuticals
Institutional Investors Weigh In On Recursion Pharmaceuticals
Several institutional investors have recently bought and sold shares of RXRX. Mubadala Investment Co PJSC purchased a new stake in Recursion Pharmaceuticals during the fourth quarter worth approximately $128,041,000. Nikko Asset Management Americas Inc. boosted its stake in shares of Recursion Pharmaceuticals by 161.2% in the fourth quarter. Nikko Asset Management Americas Inc. now owns 9,203,780 shares of the company’s stock valued at $90,565,000 after purchasing an additional 5,680,656 shares during the period. ARK Investment Management LLC boosted its stake in shares of Recursion Pharmaceuticals by 14.5% in the second quarter. ARK Investment Management LLC now owns 28,142,918 shares of the company’s stock valued at $211,072,000 after purchasing an additional 3,555,357 shares during the period. Norges Bank purchased a new position in shares of Recursion Pharmaceuticals in the fourth quarter valued at $34,825,000. Finally, Baillie Gifford & Co. boosted its stake in shares of Recursion Pharmaceuticals by 10.5% in the second quarter. Baillie Gifford & Co. now owns 26,589,936 shares of the company’s stock valued at $199,425,000 after purchasing an additional 2,522,132 shares during the period. 89.06% of the stock is currently owned by hedge funds and other institutional investors.
About Recursion Pharmaceuticals
Recursion Pharmaceuticals, Inc operates as a clinical-stage biotechnology company, engages in the decoding biology by integrating technological innovations across biology, chemistry, automation, data science, and engineering to industrialize drug discovery. The company develops REC-994, which is in Phase 2 clinical trial to treat cerebral cavernous malformation; REC-2282, which is in Phase 2/3 clinical trial for the treatment of neurofibromatosis type 2; REC-4881, which is in Phase 1b/2 clinical trial to treat familial adenomatous polyposis; REC-3964, which is in Phase 1 clinical trial to treat Clostridioides difficile infection; and REC-4881, which is in Phase 2 clinical trial to treat AXIN1 or APC mutant cancers.
Featured Stories
- Five stocks we like better than Recursion Pharmaceuticals
- The 3 Best Fintech Stocks to Buy Now
- Is Merck Stock Undervalued After Its Colossal Earnings Growth?
- What Are Dividends? Buy the Best Dividend Stocks
- Top 5 ETFs for Every Investor: From Semiconductors to Defense
- Find and Profitably Trade Stocks at 52-Week Lows
- Blade Air Mobility: This Under-the-Radar Stock Could Double Soon
Receive News & Ratings for Recursion Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Recursion Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.